REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Ryan Smith

Influencer

Ryan Smith

About

Ryan Smith (born June 28, 1978) is an American billionaire businessman and chairman of Smith Entertainment Group. He is the executive chairman and co-founder of Qualtrics, an experience management company based in Provo, Utah. Smith is also owner of the Utah Jazz of the National Basketball Association (NBA) and the Utah Mammoth of the National Hockey League (NHL) in Salt Lake City. He was also a former co-owner of Real Salt Lake of Major League Soccer (MLS).

Videos

Matthew Dawson & Dr. Abid Husain on Longevity & Epigenetic Testing

From Data to Dialogue: A Practical Guide for Translating Epigenetic Reports in Patient Conversations

How to Collect A Sample

How Fast Are You Really Aging? | DunedinPACE Epigenetic Clock Explained

TruHealth: The Future of Personalized Patient Care

What Interventions Affect Biological Age?

Multiple Aging Clocks: Which to Use and Why?

The Truth About Biological Age Tests: Dr. Matt Dawson Reveals the Latest Insights

Applications of Epigenetic Aging Clocks & Methylation Risk using Whole Genome Methylation Profiling

NEW Report Alert: Organ system clock developed with Yale